Open AccessMicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met
Author(s) -
Xin Xu,
Wenjing Jiang,
Peng Han,
Jingyan Zhang,
Liquan Tong,
Xueying Sun
Publication year - 2022
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s349369
Subject(s) - lenvatinib , cancer research , microrna , apoptosis , cell growth , cell cycle , sorafenib , protein kinase b , cell culture , hepatocellular carcinoma , signal transduction , biology , microbiology and biotechnology , biochemistry , genetics , gene
Lenvatinib is a first-line multikinase inhibitor for advanced hepatocellular carcinoma (HCC), but resistance to the drug remains a major hurdle for its long-term anti-cancer activity. This resistance is thought to be due to overexpression of c-Met. This study aims to identify potential upstream microRNAs (miRNAs) that regulate c-Met, investigate the underlying mechanisms, and seek potential strategies that may reverse such resistance.